PE20141382A1 - Inhibidor de la fosfoinositida-3-quinasa con un grupo de union a zinc - Google Patents
Inhibidor de la fosfoinositida-3-quinasa con un grupo de union a zincInfo
- Publication number
- PE20141382A1 PE20141382A1 PE2013002160A PE2013002160A PE20141382A1 PE 20141382 A1 PE20141382 A1 PE 20141382A1 PE 2013002160 A PE2013002160 A PE 2013002160A PE 2013002160 A PE2013002160 A PE 2013002160A PE 20141382 A1 PE20141382 A1 PE 20141382A1
- Authority
- PE
- Peru
- Prior art keywords
- phosphoinositide
- kinase
- inhibitor
- zinc
- binding group
- Prior art date
Links
- 108091007960 PI3Ks Proteins 0.000 title 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000011701 zinc Substances 0.000 title 1
- 229910052725 zinc Inorganic materials 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470849P | 2011-04-01 | 2011-04-01 | |
| US201161559489P | 2011-11-14 | 2011-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141382A1 true PE20141382A1 (es) | 2014-11-04 |
Family
ID=46931927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002160A PE20141382A1 (es) | 2011-04-01 | 2012-03-30 | Inhibidor de la fosfoinositida-3-quinasa con un grupo de union a zinc |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US8710219B2 (enExample) |
| EP (2) | EP2694075B1 (enExample) |
| JP (3) | JP6242331B2 (enExample) |
| KR (2) | KR20180108848A (enExample) |
| CN (2) | CN105461736B (enExample) |
| AU (1) | AU2012236367B2 (enExample) |
| BR (1) | BR112013025340B1 (enExample) |
| CA (1) | CA2830822C (enExample) |
| CL (1) | CL2013002823A1 (enExample) |
| CY (2) | CY1117785T1 (enExample) |
| DK (2) | DK3111938T3 (enExample) |
| EA (1) | EA022434B9 (enExample) |
| ES (2) | ES2577982T3 (enExample) |
| HR (2) | HRP20160545T1 (enExample) |
| HU (2) | HUE045041T2 (enExample) |
| IL (2) | IL228588A (enExample) |
| LT (1) | LT3111938T (enExample) |
| ME (2) | ME03523B (enExample) |
| MX (1) | MX340577B (enExample) |
| PE (1) | PE20141382A1 (enExample) |
| PL (2) | PL2694075T3 (enExample) |
| PT (2) | PT3111938T (enExample) |
| RS (2) | RS59219B1 (enExample) |
| SG (2) | SG193563A1 (enExample) |
| SI (2) | SI2694075T1 (enExample) |
| SM (2) | SMT201900435T1 (enExample) |
| TW (1) | TWI571469B (enExample) |
| WO (1) | WO2012135571A1 (enExample) |
| ZA (2) | ZA201307082B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2385832E (pt) * | 2009-01-08 | 2015-11-02 | Curis Inc | Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco |
| PT3111938T (pt) | 2011-04-01 | 2019-07-10 | Curis Inc | Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco |
| EA023521B1 (ru) | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| CN104725301A (zh) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | 一种1,2-二氢吡啶-2-酮衍生物的制备方法 |
| AU2016250972B2 (en) * | 2015-04-21 | 2019-01-17 | Chengdu Zenitar Biomedical Technology Co., Ltd. | Purinyl-n-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof |
| CN109476710B (zh) * | 2016-07-19 | 2021-11-23 | 国立植物基因组研究所 | 抗真菌病原体的新蛋白质 |
| KR20190077040A (ko) * | 2016-11-02 | 2019-07-02 | 쿠리스 인코퍼레이션 | 아연 결합 모이어티를 갖는 포스포이노시티드 3-키나아제 억제제를 이용하는 조합 요법 |
| CA3081815A1 (en) * | 2017-11-06 | 2019-05-09 | Cold Spring Harbor Laboratory | Method and compositions for forming a copper-containing complex and uses thereof |
| EP3849554B1 (en) | 2018-09-11 | 2025-01-29 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| EP3968215A1 (en) | 2020-09-09 | 2022-03-16 | Koninklijke Philips N.V. | Determining target object type and position |
| WO2023212574A1 (en) * | 2022-04-26 | 2023-11-02 | Olivia Szu Hsieh Lee Nakaya | Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| CA2476583C (en) | 2002-03-13 | 2011-07-05 | Kristof Van Emelen | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| JP4648628B2 (ja) | 2002-03-13 | 2011-03-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規な阻害剤としてのカルボニルアミノ誘導体 |
| WO2003076401A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| ES2306859T3 (es) | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de sulfonil como nuevos inhibidores de histona deacetilasa. |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| CN101153042A (zh) | 2003-01-29 | 2008-04-02 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
| CA2561617A1 (en) | 2004-04-05 | 2005-10-20 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2006040966A1 (ja) | 2004-10-08 | 2006-04-20 | Astellas Pharma Inc. | 芳香環縮合ピリミジン誘導体 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| DK1885710T3 (en) | 2005-05-18 | 2015-11-23 | Janssen Pharmaceutica Nv | SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE |
| JP5225103B2 (ja) | 2006-01-19 | 2013-07-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストン・デアセチラーゼの新規なインヒビターとしてのヘテロシクリルアルキル誘導体 |
| EP1979326B1 (en) | 2006-01-19 | 2012-10-03 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| US7888360B2 (en) | 2006-01-19 | 2011-02-15 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체 |
| PL2041139T3 (pl) | 2006-04-26 | 2012-05-31 | Hoffmann La Roche | Związki farmaceutyczne |
| AU2007243466B2 (en) | 2006-04-26 | 2012-01-19 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| EP2018366A4 (en) | 2006-05-16 | 2010-08-04 | Univ Mcgill | HYBRID MOLECULES WITH MIXED VITAMIN D RECEPTOR AGONISM AND HISTONDEACETYLASE RESISTANT PROPERTIES |
| AU2007296740B2 (en) | 2006-09-11 | 2012-09-27 | Curis, Inc. | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety |
| WO2008033746A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US20080161320A1 (en) | 2006-09-11 | 2008-07-03 | Xiong Cai | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| SG174772A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
| CA2662617C (en) | 2006-09-11 | 2014-11-18 | Changgeng Qian | Quinazoline based egfr inhibitors containing a zinc binding moiety |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| CA2667826C (en) | 2006-10-28 | 2013-10-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
| PE20081679A1 (es) | 2006-12-07 | 2008-12-18 | Hoffmann La Roche | Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso |
| CA2671845C (en) * | 2006-12-07 | 2015-03-24 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| CA2677651A1 (en) | 2007-02-15 | 2008-08-21 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| US20080234332A1 (en) | 2007-03-20 | 2008-09-25 | Xiong Cai | Raf kinase inhibitors containing a zinc binding moiety |
| TW200922590A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| WO2009036020A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
| WO2009036057A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Antiproliferative agents containing a zinc binding moiety |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US20090149511A1 (en) | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
| WO2009086012A1 (en) | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
| EP2311842A3 (en) | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
| WO2009155659A1 (en) | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
| US8196911B2 (en) | 2008-10-27 | 2012-06-12 | Honda Motor Co., Ltd. | Adjustable rate subframe mount |
| PT2385832E (pt) * | 2009-01-08 | 2015-11-02 | Curis Inc | Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| JP5709766B2 (ja) * | 2009-03-12 | 2015-04-30 | ジェネンテック， インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用 |
| AU2010314287A1 (en) | 2009-10-12 | 2012-05-03 | F. Hoffmann-La Roche Ag | Combinations of a PI3K inhibitor and a MEK inhibitor |
| CA2795952A1 (en) * | 2010-04-16 | 2011-10-20 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| PT3111938T (pt) * | 2011-04-01 | 2019-07-10 | Curis Inc | Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco |
| US20130102595A1 (en) | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| PT3313443T (pt) | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| KR20190077040A (ko) * | 2016-11-02 | 2019-07-02 | 쿠리스 인코퍼레이션 | 아연 결합 모이어티를 갖는 포스포이노시티드 3-키나아제 억제제를 이용하는 조합 요법 |
-
2012
- 2012-03-30 PT PT16166266T patent/PT3111938T/pt unknown
- 2012-03-30 ME MEP-2019-179A patent/ME03523B/me unknown
- 2012-03-30 LT LTEP16166266.3T patent/LT3111938T/lt unknown
- 2012-03-30 KR KR1020187026847A patent/KR20180108848A/ko not_active Ceased
- 2012-03-30 HU HUE16166266A patent/HUE045041T2/hu unknown
- 2012-03-30 PL PL12764605.7T patent/PL2694075T3/pl unknown
- 2012-03-30 SG SG2013070883A patent/SG193563A1/en unknown
- 2012-03-30 RS RSP20190842 patent/RS59219B1/sr unknown
- 2012-03-30 CN CN201610034817.XA patent/CN105461736B/zh active Active
- 2012-03-30 DK DK16166266.3T patent/DK3111938T3/da active
- 2012-03-30 BR BR112013025340-1A patent/BR112013025340B1/pt active IP Right Grant
- 2012-03-30 SG SG10201602569RA patent/SG10201602569RA/en unknown
- 2012-03-30 EA EA201301114A patent/EA022434B9/ru unknown
- 2012-03-30 JP JP2014502821A patent/JP6242331B2/ja active Active
- 2012-03-30 HU HUE12764605A patent/HUE028910T2/en unknown
- 2012-03-30 EP EP12764605.7A patent/EP2694075B1/en active Active
- 2012-03-30 PL PL16166266T patent/PL3111938T3/pl unknown
- 2012-03-30 CA CA2830822A patent/CA2830822C/en active Active
- 2012-03-30 DK DK12764605.7T patent/DK2694075T3/en active
- 2012-03-30 AU AU2012236367A patent/AU2012236367B2/en active Active
- 2012-03-30 ES ES12764605.7T patent/ES2577982T3/es active Active
- 2012-03-30 SI SI201230597A patent/SI2694075T1/sl unknown
- 2012-03-30 MX MX2013011132A patent/MX340577B/es active IP Right Grant
- 2012-03-30 SM SM20190435T patent/SMT201900435T1/it unknown
- 2012-03-30 EP EP16166266.3A patent/EP3111938B1/en active Active
- 2012-03-30 US US13/435,062 patent/US8710219B2/en active Active
- 2012-03-30 SI SI201231625T patent/SI3111938T1/sl unknown
- 2012-03-30 PT PT127646057T patent/PT2694075T/pt unknown
- 2012-03-30 TW TW101111283A patent/TWI571469B/zh active
- 2012-03-30 ES ES16166266T patent/ES2733128T3/es active Active
- 2012-03-30 CN CN201280026400.9A patent/CN103582483B/zh active Active
- 2012-03-30 PE PE2013002160A patent/PE20141382A1/es active IP Right Grant
- 2012-03-30 HR HRP20160545TT patent/HRP20160545T1/hr unknown
- 2012-03-30 RS RS20160457A patent/RS54903B1/sr unknown
- 2012-03-30 ME MEP-2016-116A patent/ME02451B/me unknown
- 2012-03-30 KR KR1020137028748A patent/KR101902325B1/ko active Active
- 2012-03-30 WO PCT/US2012/031361 patent/WO2012135571A1/en not_active Ceased
-
2013
- 2013-09-19 ZA ZA2013/07082A patent/ZA201307082B/en unknown
- 2013-09-29 IL IL228588A patent/IL228588A/en active IP Right Grant
- 2013-09-30 CL CL2013002823A patent/CL2013002823A1/es unknown
-
2014
- 2014-03-05 US US14/197,769 patent/US9249156B2/en active Active
- 2014-08-21 ZA ZA2014/06167A patent/ZA201406167B/en unknown
-
2015
- 2015-12-28 US US14/979,887 patent/US9657032B2/en active Active
-
2016
- 2016-06-16 SM SM201600179T patent/SMT201600179B/it unknown
- 2016-07-14 CY CY20161100683T patent/CY1117785T1/el unknown
- 2016-08-08 JP JP2016155625A patent/JP6275784B2/ja active Active
- 2016-10-30 IL IL248597A patent/IL248597B/en active IP Right Grant
-
2017
- 2017-04-25 US US15/496,318 patent/US10111864B2/en active Active
-
2018
- 2018-01-10 JP JP2018001910A patent/JP2018052987A/ja not_active Withdrawn
- 2018-10-03 US US16/150,845 patent/US10543197B2/en active Active
-
2019
- 2019-06-17 HR HRP20191091TT patent/HRP20191091T1/hr unknown
- 2019-07-17 CY CY20191100760T patent/CY1121825T1/el unknown
-
2020
- 2020-01-07 US US16/736,081 patent/US11135205B2/en active Active
-
2021
- 2021-09-09 US US17/470,410 patent/US11654136B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290800A1 (ru) | Гетероциклическое соединение | |
| EA201500173A1 (ru) | Фунгицидные композиции | |
| CR20160098A (es) | Polimorfo de los inhibidores de la syk | |
| ECSP13012540A (es) | Compuestos y composiciones novedosos para la inhibición de nampt | |
| UA110338C2 (xx) | Хімічні сполуки | |
| CU24406B1 (es) | 1-{[(2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2-il]metoxi}-7 -metoxiisoquinolin-6-carboxamida | |
| MX2015002616A (es) | Sintesis de bis(fluorosulfonil)imida. | |
| UA113643C2 (xx) | N-цикліламіди як нематоциди | |
| CO7220321A2 (es) | Método para producir un aditivo así como carbonato de calcio a partir de agregado de concreto así como un dispositivo para realizar el procedimiento | |
| UY34145A (es) | Compuestos inhibidores de metaloenzimas | |
| ECSP15043280A (es) | Nuevos compuestos y composiciones para la inhibición de fasn | |
| MX2013012760A (es) | Nuevos compuestos y composiciones para la inhibicion de nampt. | |
| CR20120444A (es) | Un proceso usando reactivos de grignard | |
| EA201590979A1 (ru) | Способы и промежуточные химические соединения для получения фармацевтических средств | |
| CO6630142A2 (es) | Compuestos de hidroxama de indolilo o indolinilo | |
| PH12015500008B1 (en) | Dimethyl-benzoic acid compounds | |
| AR112787A2 (es) | Compuestos 1,5-difenil-penta-1,4-dien-3-ona | |
| MX359146B (es) | Compuesto como inhibidor de señalización wnt, composición y uso de los mismos. | |
| CL2012003491A1 (es) | Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva. | |
| CR20150245A (es) | Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer | |
| NZ711192A (en) | Process for making benzoxazepin compounds | |
| AR117002A2 (es) | Proceso para la preparación de inhibidores de quinasa c-fms | |
| UA113086C2 (xx) | Піразольні сполуки як інгібітори sglt1 | |
| CY1121116T1 (el) | Νεα μεθοδος για την συνθεση αγομελατινης | |
| TR201902673T4 (tr) | Medetomidin sentezinde yararlı olan 3-arilbütanlar gibi bileşiklerin hazırlanması için işlemler. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |